Dose-Finding Designs for Early-Phase Cancer Clinical Trials A Brief Guidebook to Theory and Practice /

This book provides a comprehensive introduction to statistical methods for designing early phase dose-finding clinical trials. It will serve as a textbook or handbook for graduate students and practitioners in biostatistics and clinical investigators who are involved in designing, conducting, monito...

Full description

Bibliographic Details
Main Authors: Daimon, Takashi (Author, http://id.loc.gov/vocabulary/relators/aut), Hirakawa, Akihiro (http://id.loc.gov/vocabulary/relators/aut), Matsui, Shigeyuki (http://id.loc.gov/vocabulary/relators/aut)
Corporate Author: SpringerLink (Online service)
Format: Electronic eBook
Language:English
Published: Tokyo : Springer Japan : Imprint: Springer, 2019.
Edition:1st ed. 2019.
Series:JSS Research Series in Statistics,
Subjects:
Online Access:Full Text via HEAL-Link
Description
Summary:This book provides a comprehensive introduction to statistical methods for designing early phase dose-finding clinical trials. It will serve as a textbook or handbook for graduate students and practitioners in biostatistics and clinical investigators who are involved in designing, conducting, monitoring, and analyzing dose-finding trials. The book will also provide an overview of advanced topics and discussions in this field for the benefit of researchers in biostatistics and statistical science. Beginning with backgrounds and fundamental notions on dose finding in early phase clinical trials, the book then provides traditional and recent dose-finding designs of phase I trials for, e.g., cytotoxic agents in oncology, to evaluate toxicity outcome. Included are rule-based and model-based designs, such as 3 + 3 designs, accelerated titration designs, toxicity probability interval designs, continual reassessment method and related designs, and escalation overdose control designs. This book also covers more complex and updated dose-finding designs of phase I-II and I/II trials for cytotoxic agents, and cytostatic agents, focusing on both toxicity and efficacy outcomes, such as designs with covariates and drug combinations, maximum tolerated dose-schedule finding designs, and so on.
Physical Description:XV, 133 p. 7 illus., 3 illus. in color. online resource.
ISBN:9784431555858
ISSN:2364-0057
DOI:10.1007/978-4-431-55585-8